



Weekly Report on Severe Acute Respiratory Infection (SARI), Week 15 2024 (week ending 14/04/2024)

This report includes data on SARI hospitalised cases, aged 15 years and older who were admitted to St. Vincent's University Hospital (SVUH), Dublin, up to week 15 2024. Please note that this report pertains to one hospital site only, data are not nationally representative. Therefore, caution is advised when interpreting rates and trends outlined in this report, as these may fluctuate due to the low case numbers.

Key points

Week 15 2024 (week ending 14/04/2024):

- **Number of cases:** 12 SARI cases admitted to the SARI hospital site, compared to 11 cases in week 14 2024 (9.1% increase).
- **Incidence rate per hospital catchment population:** 3.8 per 100,000 population aged 15 years and older, compared to 3.5 per 100,000 in week 14 2024.
- **Incidence rate per emergency hospitalisations:** 37.2 per 1,000, compared to 35.8 per 1,000 in week 14 2024 (3.9% increase).
- **Age profile:** 11 (91.7%) SARI cases were aged ≥ 65 years; Median age: 73 years; IQR: 68-81 years.
- **Underlying medical conditions:** 11 (91.7%) SARI cases reported having underlying medical conditions.
- **PCR testing:** Of those tested, no cases tested positive for SARS-CoV-2, influenza or RSV.

Last four weeks (weeks 12 2024 - 15 2024)

- **Number of cases:** 51 SARI cases admitted to the SARI hospital site.
- **Age profile:** 41 (80.4%) SARI cases were aged ≥ 65 years; Median age: 76 years; IQR: 66-82 years.
- **Underlying medical conditions:** 48 (94.1%) SARI cases reported having underlying medical conditions.
- **PCR testing:** Of those tested, two (3.9%) tested positive for SARS-CoV-2; none tested positive for influenza or RSV.
- **SARS-CoV-2 whole genome sequencing (WGS):** *There can be a lag-time before WGS results are available.* Among those sequenced (n=1), one (100%) identified as variant BA.2 sub-lineage JN.1 and its sub-lineages.

Season 2023/2024 to date (weeks 40 2023 - 15 2024)

Collection of discharge data is a manual process, there is a significant lag time between discharge and data collection. Vaccination data is available approximately one week after cases are notified.

- **Number of cases:** 419 SARI cases admitted to the SARI hospital site.
- **PCR testing:** Of those tested, 45 (11.1%) tested positive for SARS-CoV-2; 54 (13.3%) tested positive for influenza (6 A(not subtyped); 31 A(H3); 17 A(H1)pdm09) and 19 (4.7%) tested positive for RSV.
- **Vaccination status:** Of those who tested positive for SARS-CoV-2 with known vaccination status (n=38), 19 (50%) had not received a COVID-19 vaccine dose within 180 days prior to their episode of illness. Of those who tested positive for influenza with known vaccination status (n= 51), 23 (45.1%) had not received this season's influenza vaccine prior to their episode of illness.
- **ICU admissions:** Among those for whom admission to ICU and/or respiratory status is known (n=416), 216 (51.9%) reported admission to ICU and/or required respiratory support.
- **Outcome:** Of those discharged, with known outcome (n=315), 35 (11.1%) SARI cases died in hospital.

Table of contents

Table of contents.....	2
Background.....	3
Methods.....	3
Case definition.....	3
Denominator data.....	4
Laboratory testing.....	4
Data collection and reporting.....	4
The influenza season.....	4
Reference dates.....	5
Results.....	6
SARI cases and incidence rates.....	6
Demographics.....	7
Underlying medical conditions and risk factors.....	8
Symptoms.....	10
Severe clinical course during hospitalisation.....	11
Laboratory testing for SARS-CoV-2, Influenza and RSV.....	12
Outcome.....	16
Vaccination status.....	16
Acknowledgements.....	19
Technical notes.....	19
Appendix.....	20
Table A1.....	20
Table A2.....	20
Table A3.....	21

Background

Severe acute respiratory infection (SARI) is of major relevance to public health worldwide. Surveillance of SARI is essential to monitor the (co-) circulation of respiratory pathogens and to assess disease severity. Data collected as part of SARI surveillance can provide important early warning information in the context of respiratory disease outbreaks and pandemics. SARI data can also be used as a platform to measure vaccine and antiviral effectiveness and impact. The objectives of SARI surveillance are:

- To describe the number and incidence of SARI cases by aetiology, time, place and person
- To describe and monitor trends, intensity of activity and severity of SARI infections
- To identify groups at risk of severe disease
- To detect unusual and unexpected events
- To assess the SARI burden of disease in the participating hospital
- To assess and monitor vaccine effectiveness

Methods

SARI surveillance was implemented in one tertiary care adult hospital: St. Vincent's University Hospital (SVUH), Dublin. Surveillance commenced on the 5th of July 2021. The SARI surveillance system includes people who are aged 15 years or older.

Case definition

SARI cases are identified from new admissions through the Emergency Department, based on clinical symptoms. Patients that develop SARI during their admission, or are admitted through alternate routes, are not included.

Clinical SARI case:

The European Centre for Disease Prevention and Control (ECDC) clinical SARI case definition is used for SARI surveillance in Ireland since week 34 2021:

- ECDC SARI definition: A hospitalised¹ person with acute respiratory infection, with at least one of the following symptoms: cough, fever, shortness of breath OR sudden onset of anosmia, ageusia or dysgeusia with onset of symptoms within 14 days prior to hospital admission.

¹ Hospitalised for at least 24 hours

Denominator data

Denominator data for the hospital catchment area are based on the Census of Population, 2022. The hospital catchment data were prepared and provided by the Health Intelligence Unit (HIU) of the Health Service Executive (HSE) and were extracted from Health Atlas Ireland on 15/12/2023.

Weekly denominator data on all-cause hospital admissions, through the Emergency Department, are provided by the SVUH Statistics Department.

Laboratory testing

SARS-CoV-2, influenza, and RSV PCR testing is carried out on admission.

SARI samples that are positive for SARS-CoV-2 and that have a cycle threshold (Ct) value <25 are referred for whole genome sequencing (WGS). All WGS testing was performed in the NVRL up to week 44 2022. The molecular laboratory in SVUH has been identified as a spoke WGS testing site as part of the national SARS-CoV-2 WGS surveillance programme. From week 45 2022, SARI WGS testing has been performed on-site at SVUH.

Samples that are PCR positive for influenza are sent to the National Virus Reference Laboratory (NVRL) for influenza typing/subtyping/genetic and antigenic characterisation.

Data collection and reporting

Clinical data are collected and managed using REDCap electronic data capture tools hosted at University College Dublin. Laboratory data are extracted from APEX, the laboratory information management system (LIMS), using IBM Cognos software hosted at SVUH.

Case-based data are reported by SVUH to the HSE Health Protection Surveillance Centre (HPSC) on a weekly basis. Data are also reported by HPSC to ECDC via The European Surveillance System (TESSy) on weekly basis as part of European level SARI surveillance.

COVID-19 vaccination data are obtained from the National COVID-19 Vaccination Management System (COVAX) and linked to SARI cases by the HSE-Integrated Information Service (IIS), where data are available.

The influenza season

The influenza surveillance season runs from week 40 (early October) to week 20 (end of May). During this time, seasonal viruses usually circulate at higher levels, compared to the summer period (weeks 21 to 39). The seasonal comparisons used in this report refer to the influenza surveillance season.

Reference dates

05/07/2021 (Week 27 2021) – commencement of SARI surveillance project
27/09/2021 (Week 39 2021) – rollout of the first COVID-19 booster vaccination campaign
22/04/2022 (Week 16 2022) – rollout of the second COVID-19 booster vaccination campaign
03/10/2022 (Week 40 2022) – rollout of the third COVID-19 booster vaccination campaign
28/04/2023 (Week 17 2023) – rollout of the fourth COVID-19 booster vaccination campaign
02/10/2023 (Week 40 2023) – rollout of the fifth COVID-19 booster vaccination campaign
04/10/2021 (Week 40 2021) - start of the 2021/2022 season
03/10/2022 (Week 40 2022) - start of the 2022/2023 season
02/10/2023 (Week 40 2023) - start of the 2023/2024 season

Week number refers to the week of hospital admission. Weeks are from Monday to Sunday, as per the international ISO week².

² Monday to Sunday (ISO week) used as per ECDC/WHO/International reporting protocol.

Results

Data were extracted from the HPSC SARI surveillance database on **17/04/2024**. Data are provisional and subject to ongoing review, validation and update. As a result, figures presented in this report may differ from previously published figures.

SARI cases and incidence rates

In total, 419 SARI cases were admitted to St. Vincent’s University Hospital (SVUH) during the current season (weeks 40 2023 - 15 2024), 491 SARI cases were admitted during the same period in the 2022/2023 season (weeks 40 2022 - 15 2023).

In week 15 2024:

- 12 SARI cases were reported, a 9.1% increase compared to 11 SARI cases reported in week 14 2024 (Figure 1)
- The SARI incidence rate was 3.8 per 100,000 hospital catchment population aged 15 years and older, compared to the rate of 3.5 per 100,000 in week 14 2024.
- The incidence rate per emergency hospitalisations was 37.2 per 1,000 emergency admissions, a 3.9% increase compared to the rate of 35.8 per 1,000 emergency admissions in week 14 2024.




Figure 1: Number and incidence of SARI hospitalised cases (emergency admissions) by week of hospital admission, week 40 2021 to week 15 2024 (n=1828)

Demographics

In week 15 2024, of the 12 SARI cases reported:

- Females accounted for a higher proportion of SARI cases, n=7 (58.3%) (Table 1)
- Median age of SARI cases admitted was 73 years (interquartile range: 68-81 years)
- Age specific incidence rate amongst those aged 65 years and older was 17.5 per 100,000 compared to 15.9 per 100,000 in week 14 2024.

The incidence rate per 100,000 hospital catchment population by age group is shown in Figure 2.

Table 1: Number and proportion of SARI cases by sex and age, for the current week, last four weeks (weeks 12 - 15 2024), current 2023/2024 season (weeks 40 2023 - 15 2024) and the previous 2022/2023 season (weeks 40 2022 - 15 2023)

Season	Current week		Last four weeks		Current season		Previous season	
Week/Year	W15 2024		W12 2024- W15 2024		W40 2023- W15 2024		W40 2022- W15 2023	
	n	(%)	n	(%)	n	(%)	n	(%)
All SARI cases	12		51		419		491	
Gender								
Male	5	41.7	25	49.0	212	50.6	230	46.8
Female	7	58.3	26	51.0	207	49.4	261	53.2
Age (years)								
Mean	74		71		72		71	
Median	73		76		77		75	
IQR	68-81		66-82		66-84		64-83	
Range	57-86		19-96		18-100		17-101	
Age groups (years)								
15-24	0	0.0	3	5.9	9	2.1	9	1.8
25-34	0	0.0	1	2.0	12	2.9	11	2.2
35-44	0	0.0	2	3.9	23	5.5	20	4.1
45-54	0	0.0	1	2.0	19	4.5	27	5.5
55-64	1	8.3	3	5.9	29	6.9	71	14.5
65-74	5	41.7	13	25.5	93	22.2	106	21.6
75-84	4	33.3	20	39.2	143	34.1	152	31.0
85+	2	16.7	8	15.7	91	21.7	95	19.3




Figure 2: SARI incidence rate per 100,000 hospital catchment population by age group and week of hospital admission, from week 40 2021 to week 15 2024 (n=1828)

Underlying medical conditions and risk factors

The number and proportion of individuals with underlying medical conditions, where known, among those that reported having underlying medical conditions are displayed in Table 2.

Weekly proportions can be based on small numbers and vary from week to week, caution is therefore advised when interpreting changes in weekly proportions.

SARI cases could be reported with one or more underlying medical conditions, only cases where underlying medical conditions are reported are included in Table 2.

Table 2: Number and proportion of SARI cases with underlying medical conditions, reported on hospital admission, for the current week, last four weeks (weeks 12 - 15 2024), current 2023/2024 season (weeks 40 2023 - 15 2024) and the previous 2022/2023 season (weeks 40 2022 - 15 2023).

Period	Current week		Last four weeks		Current season		Previous season	
	W15 2024		W12 2024- W15 2024		W40 2023- W15 2024		W40 2022- W15 2023	
Weeks								
Medical conditions	n	%	n	%	n	%	n	%
Total cases	11		48		388		464	
Heart disease	5	45.5	24	50.0	168	43.3	176	37.9
Hypertension	3	27.3	15	31.2	134	34.5	188	40.5
Lung disease	6	54.5	19	39.6	131	33.8	172	37.1
Cancer	3	27.3	5	10.4	70	18.0	72	15.5
Neurological disease	3	27.3	12	25.0	64	16.5	107	23.1
Asthma	0	0.0	1	2.1	44	11.3	73	15.7
Diabetes	2	18.2	10	20.8	69	17.8	78	16.8
Kidney disease	0	0.0	7	14.6	48	12.4	30	6.5
Intellectual disability	0	0.0	2	4.2	6	1.5	17	3.7
Immunocompromised	0	0.0	1	2.1	6	1.5	4	0.9
Obesity	0	0.0	1	2.1	3	0.8	12	2.6
Cystic fibrosis	0	0.0	2	4.2	6	1.5	1	0.2
Asplenia*	0	0.0	0	0.0	0	0.0	-	-
Dementia*	0	0.0	5	10.4	41	10.6	-	-
Down syndrome*	0	0.0	0	0.0	1	0.3	-	-
Long COVID*	0	0.0	0	0.0	0	0.0	-	-
Tuberculosis*	0	0.0	0	0.0	1	0.3	-	-
Rheumatological disease*	0	0.0	2	4.2	21	5.4	-	-
Other chronic conditions**	4	36.4	13	27.1	141	36.3	240	51.7

*Data collection for these underlying medical conditions began in week 49 2023.

**Data reported on other chronic conditions may include some of the chronic conditions listed above, these data are under review and may change over time

Among female SARI cases aged 15-49 years admitted during the 2023/2024 season (weeks 40 2023 - 15 2024), 1 (3.3%) case was reported as being pregnant at the time of admission. During the same period in the 2022/2023 season (weeks 40 2022 - 15 2023), 3 (10.7%) SARI cases were reported as being pregnant at the time of admission.

Among those admitted during the 2023/2024 season for whom healthcare worker status is known, 6 (1.4%) cases were reported as being healthcare workers at the time of admission. During the same period in the 2022/2023 season, 6 (1.2%) SARI cases were reported as being healthcare workers.

Symptoms

Information on clinical symptoms, either at or prior to hospital admission, was reported for all SARI cases. The most common symptoms reported were cough and shortness of breath (Table 3).

Table 3: Number and proportion of SARI cases with clinical symptoms, either at or prior to hospital admission, for the current week, last four weeks (weeks 12 - 15 2024), current 2023/2024 season (weeks 40 2023 - 15 2024) and the previous 2022/2023 season (weeks 40 2022 - 15 2023).

Period	Current week		Last four weeks		Current season		Previous season	
	W15 2024		W12 2024- W15 2024		W40 2023- W15 2024		W40 2022- W15 2023	
Weeks	n	%	n	%	n	%	n	%
Clinical symptoms*	n	%	n	%	n	%	n	%
Total cases	12		51		419		491	
Cough	10	83.3	34	66.7	301	71.8	391	79.6
Shortness of breath	10	83.3	42	82.4	309	73.7	359	73.1
Fever	4	33.3	20	39.2	187	44.6	247	50.3
General deterioration	2	16.7	10	19.6	135	32.2	228	46.4
Malaise	2	16.7	5	9.8	67	16.0	41	8.4
Headache	0	0.0	1	2.0	17	4.1	22	4.5
Muscular pain	0	0.0	0	0.0	17	4.1	31	6.3
Sore throat	0	0.0	0	0.0	24	5.7	26	5.3
Ageusia	0	0.0	0	0.0	1	0.2	1	0.2
Anosmia	0	0.0	0	0.0	1	0.2	2	0.4
Dysgeusia	0	0.0	0	0.0	1	0.2	0	0.0
Sepsis**	3	25.0	9	17.6	29	6.9	-	-
Acute confusion**	0	0.0	4	7.8	24	5.7	-	-
Vomiting**	0	0.0	2	3.9	23	5.5	-	-
Apnoea**	0	0.0	1	2.0	2	0.5	-	-
Diarrhoea**	1	8.3	2	3.9	10	2.4	-	-

*SARI cases could be reported with one or more clinical symptoms

**Data collection for these symptoms began in week 49 2023.

Severe clinical course during hospitalisation

Information on the clinical course during hospitalisation is only available after discharge, and there may be a delay between discharge and data collection, due to the manual data collection methods required. Among those for whom discharge information is available the most common complication reported was pneumonia (Table 4).

Data collection is ongoing for those not yet discharged from hospital.

Table 4: Number and proportion of SARI cases by complication, for the current 2023/2024 season (weeks 40 2023 - 15 2024), the previous 2022/2023 season (weeks 40 2022 - 15 2023), and cases admitted between week 40 2022 and week 15 2024

Season(s)	Current season		Previous season		Since W40 2022	
Week/Year	W40 2023- W15 2024		W40 2022- W15 2023		W40 2022- W15 2024	
Complications*	n	%	n	%	n	%
Total discharged cases	315		491		1077	
Pneumonia	30	9.5	33	6.7	128	11.9
ARDS	12	3.8	17	3.5	50	4.6
Sepsis	20	6.3	12	2.4	39	3.6
Multiorgan failure	5	1.6	4	0.8	13	1.2
Myocarditis	1	0.3	0	0.0	1	0.1
Encephalitis	0	0.0	0	0.0	0	0.0
Bronchiolitis	0	0.0	0	0.0	1	0.1
Acute kidney injury**	23	7.3	-	-	25	2.3
Heart failure**	7	2.2	-	-	10	0.9
Secondary bacterial infection**	2	0.6	-	-	2	0.2
Other complications***	61	19.4	129	26.3	253	23.5
No complications	187	59.4	319	65.0	636	59.1

*SARI cases could be reported with one or more complications.

**Data collection for these complications began in week 49 2023.

***Data reported on "other complications" may include some of the complications listed above, these data are under review and may change over time.

Table 5: Number and proportion of SARI cases by respiratory support and ICU admission, for the current 2023/2024 season (weeks 40 2023 - 15 2024), the previous 2022/2023 season (weeks 40 2022 - 15 2023), and cases admitted between week 40 2022 and week 15 2024

Season(s) Week/Year	Current season		Previous season		Since W40 2022	
	W40 2023- W15 2024		W40 2022- W15 2023		W40 2022- W15 2024	
	n	%	n	%	n	%
Respiratory support status known	313		491		1075	
High-flow oxygen therapy*	208	66.5	306	62.3	681	63.3
Invasive ventilation	7	2.2	15	3.1	25	1.4
No respiratory support	98	31.3	170	34.6	369	34.3
ICU status known	416		491		1179	
ICU/ventilated**	216	51.9	321	65.4	708	60.1
Admitted to ICU	9	2.2	29	5.9	49	4.2
Admitted and discharged	9	2.2	29	5.9	49	4.2
ICU length of stay (days)						
Mean	7		9		8	
Median	6		6		5	
Interquartile range	5-10		3-11		3-10	
Range	2-15		1-42		<1-42	

*Non-invasive ventilation

**SARI cases which required invasive and/or non-invasive ventilation and/or ICU admission

Laboratory testing for SARS-CoV-2, Influenza and RSV

PCR testing

SARI cases are tested by PCR for SARS-CoV-2, influenza and RSV on admission.

In week 15 2024:

- SARS-CoV-2 PCR testing was carried out on all SARI cases, no cases tested positive, the last SARS-CoV-2 positive cases was in week 13 2024.
- Influenza PCR testing was carried out on all SARI cases, no cases tested positive, the last positive influenza cases was in week 11 2024.
- Respiratory syncytial virus (RSV) PCR testing was carried out on all SARI cases, no cases tested positive, the last RSV positive cases was in week 6 2024.

The weekly positivity rate of SARI cases for the three acute respiratory pathogens are presented in Figure 3. Table 6 displays the number and proportion of SARI cases tested by PCR and positive for SARS-CoV-2, influenza and RSV, and the type/subtype for all influenza PCR positive test results.




Figure 3: Percentage of SARI cases with a positive laboratory test result for SARS-CoV-2, influenza and RSV by week, from week 40 2021 to week 15 2024

In the current season (weeks 40 2023 – 15 2024), two cases with co-infections were reported; one case tested positive for SARS-CoV-2 and influenza AH3, and one case tested positive for SARS-CoV-2 and RSV.

Table 6: Number of positive SARS-CoV-2, influenza, and RSV SARI cases, and influenza type/subtype for the current week, previous two weeks (week 14 2024, week 13 2024), current 2023/2024 season (weeks 40 2023 - 15 2024), and the 2022/2023 season (weeks 40 2022 - 15 2023).

Period	Individual weeks						Current season		Previous season	
	W15 2024		W14 2024		W13 2024		W40 2023- W15 2024		W40 2022- W15 2023	
Test result	n	%	n	%	n	%	n	%	n	%
SARS-CoV-2										
Total tested	12		11		16		407		485	
Positive	0	0.0	0	0.0	1	6.2	45	11.1	93	22.9
RSV										
Total tested	12		11		16		407		481	
Positive	0	0.0	0	0.0	0	0.0	19	4.7	42	10.3
Influenza										
Total tested	12		11		16		407		481	
Positive	0	0.0	0	0.0	0	0.0	54	13.3	67	16.5
Influenza A (H3)	0	0.0	0	0.0	0	0.0	31	7.6	31	7.6
Influenza A (H1)pdm09	0	0.0	0	0.0	0	0.0	17	4.2	30	7.4
Influenza A (not subtyped)	0	0.0	0	0.0	0	0.0	6	1.5	4	1.0
Influenza B (Victoria)	0	0.0	0	0.0	0	0.0	0	0.0	2	0.5
Influenza B (no lineage)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

SARS-CoV-2 Genomic analysis

There can be a lag-time before WGS results are available. The WGS data presented is up to week 12 2024

Sequencing results have been received for 375 SARS-CoV-2 SARI cases admitted between week 40 2021 and week 12 2024 (Figure 4).

BA.2 sub-lineage JN.1 (and its sub-lineages) is the dominant variant circulating among SARI cases admitted to the hospital site in the current season. Among SARS-CoV-2 positive SARI cases admitted during the current season (weeks 40 2023 - 15 2024), for whom WGS data are available (n=39), 23 (59.0%) were variant BA.2 sub-lineage JN.1 (and its sub-lineages), 8 (20.5%) were XBB.1.5-like lineages, and 8 (20.5%) were XBB.1.5-like+F456L mutation.

Further information on SARI variants is available in the appendix (Table A1 and A2). For further information on circulating variants in Ireland, see the COVID-19 virus variants reports on the HPSC website³.




Figure 4: Number of SARI cases sequenced and reported, by week of hospitalisation, week 40 2021 to week 12 2024 (n=375)

*Includes sub-lineage JN.1

**All other variants

Note: As described by the ECDC, ‘XBB.1.5-like’ and ‘XBB.1.5-like + F456L’ refer to groupings of lineages that share sets of spike protein mutations

³ <https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/surveillance/summaryofcovid-19virusvariantsinireland/>

Outcome

Collection of discharge data is a manual process, therefore there is a significant lag time between patient discharge and data collection.

Of the 419 SARI cases admitted to the SARI hospital site during the current 2023/2024 season (weeks 40 2023 - 15 2024), 315 (75.2%) have discharge data available. Of those admitted during the same period in the 2022/2023 season (weeks 40 2022 - 15 2023), 491 (100%) cases have been discharged (Table 7).

Among SARI cases admitted during the current 2023/2024 season (weeks 40 2023 - 15 2024) and discharged with known outcome, 35 (11.1%) deaths have been reported, 19 (54.3%) were male and 16 (45.7%) were female. The median age was 83 years (IQR: 74-90 years).

Among SARI cases admitted during the 2022/2023 season (weeks 40 2022 - 15 2023) and discharged with known outcome, 51 (10.4%) died in hospital, 23 (45.1%) were male and 28 (54.9%) were female. The median age was 78 years (IQR: 74-87 years).

Table 7: Number and proportion of discharged SARI cases by outcome and hospital length of stay, for the current 2023/2024 season (weeks 40 2023 - 15 2024), the previous 2022/2023 season (weeks 40 2022 - 15 2023), and cases admitted between week 40 2022 and week 15 2024.

Season(s) Week/Year	Current season		Previous season		Since W40 2022	
	W40 2023- W15 2024		W40 2022- W15 2023		W40 2022- W15 2024	
	n	%	n	%	n	%
Known outcome	315		491		1077	
Discharged alive	280	88.9	433	88.2	966	89.7
Transferred*	0	0.0	7	1.4	8	0.7
Died in hospital	35	11.1	51	10.4	103	9.6
Hospital length of stay (days)						
Mean	10		13		12	
Median	6		6		6	
Interquartile range	3-14		3-13		3-12	
Range	1-63		1-271		1-271	

*Transferred to another hospital

Vaccination status

Vaccination data are available approximately one week after cases are notified to HPSC, therefore the vaccination status for the current week's SARI cases is recorded as unknown.

COVID-19 Vaccination status

Amongst SARI cases, admitted in the current season (weeks 40 2023 - 15 2024) who were PCR positive for SARS-CoV-2 and with known COVID-19 vaccination status, 19 (50%) had not received a vaccine dose within the six months prior to their episode of illness (Table 8).

Characteristics of **all** SARI cases by time since last COVID-19 vaccine dose and symptom onset during the current season are presented in the Appendix (Table A3). Please refer to the technical notes for the full list of definitions on COVID-19 vaccination status.

Table 8: Characteristics of SARS-CoV-2 positive SARI cases by time since last COVID-19 vaccine dose and symptom onset during the current season (weeks 40 2023-15 2024)

Note: SARS-CoV-2 positive SARI cases with unknown vaccination status, n=7 (15.6%) are excluded.

Weeks	Week 40 2023 - 14 2024		
	<180 days, N = 19 ¹	>=180 days, N = 19 ¹	Not vaccinated, N = 0 ¹
Total	19 (50.0%)	19 (50.0%)	0 (0.0%)
Age(years)			
Mean	77	74	-
Median	77	75	-
IQR	73 - 82	69 - 83	-
Range	65 - 91	33 - 92	-
Gender			
Female	7 (50.0%)	7 (50.0%)	0 (0.0%)
Male	12 (50.0%)	12 (50.0%)	0 (0.0%)
Age groups (years)			
15-49	0 (0.0%)	1 (100.0%)	0 (0.0%)
50-69	3 (42.9%)	4 (57.1%)	0 (0.0%)
70+	16 (53.3%)	14 (46.7%)	0 (0.0%)
Patient residence			
Residential care facility	5 (100.0%)	0 (0.0%)	0 (0.0%)
Private residence/home	14 (46.7%)	16 (53.3%)	0 (0.0%)
Patient residence not known	0 (0.0%)	3 (100.0%)	0 (0.0%)
Underlying medical conditions			
Yes	19 (50.0%)	19 (50.0%)	0 (0.0%)
No	0 (0.0%)	0 (0.0%)	0 (0.0%)

¹n (%)

Influenza vaccination status

Amongst the SARI cases, admitted in the current season (weeks 40 2023 - 15 2024) who were PCR positive for influenza and with known vaccination status (n=51), 23 (45.1%) had not received a dose of this current season's vaccine prior to their episode of illness (Table 9).

Table 9: Characteristics of influenza positive SARI cases by influenza vaccination status during the current season (weeks 40 2023-15 2024).

Note: Influenza positive SARI cases with unknown vaccination status, n=3 (5.6%) are excluded.

Weeks	Week 40 2023 - 15 2024	
	Vaccinated, N = 28 ¹	Not vaccinated, N = 23 ¹
Characteristic		
Total	28 (54.9%)	23 (45.1%)
Age(years)		
Mean	77	70
Median	81	72
IQR	73 - 84	60 - 80
Range	39 - 90	41 - 100
Gender		
Female	13 (48.1%)	14 (51.9%)
Male	15 (62.5%)	9 (37.5%)
Age groups (years)		
15-49	2 (50.0%)	2 (50.0%)
50-69	2 (20.0%)	8 (80.0%)
70+	24 (64.9%)	13 (35.1%)
Patient residence		
Residential care facility	5 (41.7%)	7 (58.3%)
Private residence/home	23 (59.0%)	16 (41.0%)
Underlying medical conditions		
Yes	26 (56.5%)	20 (43.5%)
No	2 (40.0%)	3 (60.0%)

¹n (%)

Acknowledgements

Sincere thanks are extended to all those who participate in SARI surveillance, including those in St. Vincent's University Hospital, the UCD Clinical Research Centre and the National Virus Reference Laboratory. Thanks to members of the HSE Integrated Information Services (IIS) for work on the SARI-COVAX data linkages.

This report was produced by the SARI surveillance team at HPSC.

This report was produced using R studio software.

Technical notes

1. SARI case
 - A SARI case refers to an individual patient episode of care.
2. Vaccination status
 - For the purposes of SARI surveillance, vaccination status of cases is as follows:

Vaccinated⁴: A case who received their last primary COVID-19 vaccine dose ≥ 14 days prior to the date of symptom onset or their last booster COVID-19 vaccine dose ≥ 7 days prior to the date of symptom onset.

Time since vaccination: For vaccinated cases, time since vaccination is calculated by subtracting the date of vaccination from the date of symptom onset and categorised as <180 days or ≥ 180 days since vaccination.

Not vaccinated, if the following applies:

- Vaccination record on the National COVID-19 Immunisation system indicates the person was vaccinated after the date of symptom onset.
- The SARI patient was reported as not vaccinated on the SARI hospital clinical questionnaire, and there is no identifiable linked record of COVID-19 vaccination on the National COVID-19 Immunisation system.

Vaccine status unknown, if:

- The SARI patient is reported on the SARI hospital clinical questionnaire as vaccinated, however there is no identifiable linked record of COVID-19 vaccination on the National COVID-19 Immunisation system. Vaccination status is reported as unknown, until verified on the National COVID-19 Immunisation system.
- The SARI patient is reported on the SARI hospital clinical questionnaire as vaccination status unknown, AND there is no identifiable linked record of COVID-19 vaccination on the National COVID-19 Immunisation system.

⁴ Refer to www.hse.ie for further information on the COVID-19 vaccination rollout

Appendix

Table A1

Number and proportion of SARI cases sequenced and reported, by pango lineage and variant, admitted during the 2023/2024 season, weeks 40-15 (n=39)

Virus Variant	Pango Lineage	Number of cases	Sequenced cases %
BA.2 lineages	JN.1	20	51.3
	JN.1.4	2	5.1
	JN.1.8.1	1	2.6
XBB.1.5 like lineages	FL.15	1	2.6
	FL.9	1	2.6
	GE.1	2	5.1
	XBB.1.5	1	2.6
	XBB.2.3	1	2.6
	XBB.2.3.11	1	2.6
	XBB.2.3.13	1	2.6
XBB.1.5like+F456L	EG.5.1	1	2.6
	EG.5.1.1	1	2.6
	EG.5.1.3	1	2.6
	HK.3	1	2.6
	HV.1	1	2.6
	JD.1.1	1	2.6
	XBB.1.16.6	2	5.1
Total		39	

Table A2

Number of SARI cases sequenced and reported by pango lineage and week of admission for the previous five weeks for which sequencing data are available.

Virus variant	Pango lineage	2024-W08	2024-W09	2024-W10	2024-W11	2024-W12	Total
BA.2	JN.1	1	0	1	1	0	3
	JN.1.4	0	1	0	0	1	2
Total		1	1	1	1	1	5

Table A3

Characteristics of **all** SARI cases by COVID-19 vaccination status by time since last COVID-19 vaccine dose and symptom onset during the current influenza season (weeks 40 2023-15 2024).

Note: SARI cases with unknown vaccination status are excluded, n=90 (21.5%)

Weeks Characteristic	Week 40 2023 - 14 2024		
	<180 days, N = 188 ¹	>=180 days, N = 139 ¹	Not vaccinated, N = 2 ¹
Total	188 (57.1%)	139 (42.2%)	2 (0.6%)
Age(years)			
Mean	77	67	-
Median	80	71	-
IQR	73 - 85	58 - 82	-
Range	18 - 100	18 - 94	-
Gender			
Female	93 (57.4%)	69 (42.6%)	0 (0.0%)
Male	95 (56.9%)	70 (41.9%)	2 (1.2%)
Age groups (years)			
15-49	11 (28.2%)	26 (66.7%)	2 (5.1%)
50-69	25 (40.3%)	37 (59.7%)	0 (0.0%)
70+	152 (66.7%)	76 (33.3%)	0 (0.0%)
Patient residence			
Residential care facility	47 (90.4%)	5 (9.6%)	0 (0.0%)
Private residence/home	134 (51.5%)	124 (47.7%)	2 (0.8%)
Other residence	1 (100.0%)	0 (0.0%)	0 (0.0%)
Patient residence not known	6 (37.5%)	10 (62.5%)	0 (0.0%)
Underlying medical conditions			
Yes	184 (58.8%)	129 (41.2%)	0 (0.0%)
No	4 (25.0%)	10 (62.5%)	2 (12.5%)

¹n (%)